New type of experimental drug active in platinum-resistant ovarian cancers

The antibody-drug conjugate DMUC5754A, a novel member of a relatively new class of drugs, showed activity in women with ovarian cancer, even those with hard-to-treat, platinum-resistant disease, in a phase I trial. Those women with the highest expression of the drug's target, MUC16, gained the most benefit from treatment, which may help researchers predict which patients will benefit from treatment.

Read the whole article on Science Daily

More from Science Daily